Abstract. Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been approved for treatment of metastatic ER+ HER2− breast cancer as monotherapy or in combination with endocrine therapy. However, ...

Abstract. Background: Mutant KRAS is an important driver of tumor and has remained an undruggable target for decades. Despite the success of mutant-specific KRASG12C inhibitors, there is limited ...

Abstract. Brentuximab vedotin (BV) is an antibody-drug conjugate directed against CD30 consisting of a monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent.

AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Research Communications ...

Abstract. Manual review of aligned reads for confirmation and interpretation of variant calls is an important step in many variant calling pipelines for next-generation sequencing (NGS) data. Visual ...

Cancer Research | 85 | 8_Supplement_1 | April 2025Journal Archive Cancer Research (1941-Present; volumes 1-current) Published twice monthly since 1987. From 1941-1986, published monthly. (ISSN ...

This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic ...

Abstract. As leaders with the American Society of Preventive Oncology (ASPO) Cancer Health Disparities Special Interest Group, we describe the role of structural racism in perpetuating cancer health ...

Metastasis is initiated and sustained through therapy by cancer cells with stem-like and immune-evasive properties, termed metastasis-initiating cells (MIC). Recent progress suggests that MICs result ...

Abstract. Pancreatic cancer is an aggressive cancer characterized by high mortality and poor prognosis with survival of less than 5 years when advanced. Several studies showed that the ivermectin has ...

Summary:. Cell surface proteins represent ideal therapeutic targets because of their accessibility to antibodies, T cell–directed therapies, and radiotherapies, but there are only 25 therapeutically ...

The future of cancer clinical trials requires a framework that can efficiently transform scientific discoveries to clinical utility through applications of innovative technologies and dynamic design ...